AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Myrbetriq (Astellas Pharma Inc.) (myrbetriq.com)
This is a high-substance, low-technical-effort site where regulatory compliance prevents excessive BS, but stale data and zero structured data create a ‘ghost in the machine’ effect. The site relies on a 15-year-old study to drive its primary urgency claim, showing a reliance on legacy evidence. It is a functionally honest but technically neglected digital property.
Immediately implement MedicalWebPage and Organization schema to ground the brand’s digital authority. Update the epidemiological data to include post-2020 real-world evidence (RWE) to address the 15-year stale-date gap. Audit the heading hierarchy to remove the quadruple-repetition of the Symptom Summary markers. Replace generic trust theatre review counts with direct outbound citations to the peer-reviewed clinical studies referenced in Study 4.
The site exhibits high substance-to-fluff ratios due to regulatory requirements, featuring specific clinical study data such as the 52-week Myrbetriq Safety Study involving 812 people. Headings like [H2] What is Myrbetriq used for? and [H2] How Does Myrbetriq Work? are functional and direct, avoiding power-word saturation. However, information density is negatively impacted by extreme redundancy; the Doctor Conversation Guide headings and Symptom Summary blocks are repeated verbatim across multiple slots. Furthermore, the core epidemiological evidence cited (EpiLUTS 2011) is 15 years stale relative to the 2026 temporal anchor, reducing the weight of its ‘1 in 3’ claim.
When chunking fails, embeddings degrade, retrieval collapses, and your content loses every competitive comparison. Generate your Semantic HTML Audit to quantify the structural friction that blocks AI comprehension.
There is virtually zero semantic drift between the homepage signal and sub-page substance. The homepage H1 Doctor Conversation Guide leads directly to functional symptom assessment tools on sub-pages, and the mechanism-of-action promises are fulfilled by the detailed animated explanations on the What is Myrbetriq page. The messaging remains consistent, targeting patients with OAB symptoms and guiding them toward a healthcare professional (HCP) consultation. Some minor technical drift is noted in the heading hierarchy where the symptom quiz structure repeats unnecessarily, but the core clinical message is unwavering.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
Trust theatre flags are high because the site displays a review_count of 3 on several pages while maintaining a proof_links_count of 0. While patient testimonials are common in pharma, presenting them without verified clinical outcome links or third-party validation constitutes trust theatre. Additionally, bold claims like ‘effective… within the first 4 to 8 weeks’ are substantiated only by internal references rather than direct outbound links to peer-reviewed publications.
Proof density is moderate; the site provides specific side-effect percentages (e.g., 9.2% for high blood pressure) and study parameters, which is high-quality evidence. However, the ratio is diluted by the lack of external verification paths (outbound links to ClinicalTrials.gov or PubMed). For every specific clinical data point, there are multiple repetitive blocks of legal text, which, while necessary, do not count as new evidentiary substance.
To review a full competitive diagnostic applied to an enterprise level technical SEO agency, including a direct comparison against Dejan, examine the complete executive audit. View the iPullRank Executive SEO Strategy Dashboard for a practical example of how perception gaps, value prop drift, and audience misalignment are surfaced in real audits.
The site follows a standard pharmaceutical ‘Product Site’ template, including the ubiquitous ISI scroll-box and resource library. Clichés like ‘Start the Conversation’ and ‘You Are Not Alone’ are industry-standard, though they serve a functional purpose in this context. The value proposition is technically unique, focused on the ‘different pathway’ (non-antimuscarinic) mechanism of action, which prevents the site from being a pure commodity copy-paste. Boilerplate sections like ‘OAB Resources’ are slightly generic but contain specific recipes and exercise tips that add marginal unique value.
A significant authority gap exists due to the total absence of structured data (schema_json is null across all 4 pages). For a major medical product, the failure to implement Organization or MedicalWebPage schema suggests a technical credibility gap. While specific experts like Nurse Practitioner Diane Newman and Dr. David Stastkin are named in the OAB Resources, they lack Person schema or sameAs links to verify their digital footprint or professional credentials.
The marketing tone is subdued and clinical, which aligns well with the demonstrated data. The site avoids ‘breakthrough’ hyperbole, instead using grounded claims like ‘Myrbetriq was shown in studies to be effective.’ The disconnect is primarily temporal; the site presents data from 2011 as current situational evidence in 2026, creating a reality-gap in the reported prevalence of the condition.
Medical Devices, Pharma & Biotech BS: Myrbetriq (Astellas Pharma Inc.) (myrbetriq.com)
The site perfectly matches the Pharma & Biotech category, adhering to strict FDA-mandated disclosure patterns. Content is focused on a specific therapeutic area (OAB) and provides the required Important Safety Information (ISI) and Prescribing Information links.
When links fail to express hierarchy, the model cannot form clusters or identify primary entities. Examine the Internal Linking Technical Guide and understand how structural signals—not navigation—define your semantic map.
“The score of 35 is driven primarily by the complete lack of technical authority (Step 5) and the presence of trust theatre patterns (Step 3). Information density (Step 1) is relatively good due to pharma regulations, though penalized for extreme content repetition. This is a very low score for a marketing site but standard for a highly-regulated pharmaceutical landing page.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 31, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Myrbetriq (Astellas Pharma Inc.) to view the most current version of their content and see directly what the company offers.